Q&A: Quadruple therapies and the future of multiple myeloma treatment
The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy ...
May 24, 2024
0
0